Brit, 20, breaks her back after fall from hotel balcony on Greek island… docs say it'll be 2 MONTHS before she can move
The nightmare incident happened on the popular holiday island of Rhodes in Greece.
4
4
Holly Seaford, 20, had been on holiday with her partner when the accident happened on Wednesday, July 9 in the early hours.
She suffered fractured four vertebrae and remains in hospital while she recovers, Wales Online has reported.
But doctors have told her partner Tate Crees that Holly may have to wait as long as two months before she can walk again.
Tate said: "She is lying flat in a hospital bed in a back brace unable to move or walk.
"Doctors have told us it'll be at least six to eight weeks before she can start to regain mobility.
"This is going to be a very difficult process."
Holly and Tate had been due to fly back from holiday on the day the of the incident.
But Holly's sister Briony has said the family can't afford to get her back home by themselves.
She said: "She's in a lot of pain and is bedbound.
"The last I heard they'd given her paracetamol. They can't effectively look after her there."
Raging wildfires spread across Greek island holiday hotspot as hotels and homes are 'evacuated'
A GoFundMe page has been set up to help bring Holly back home for further medical attention.
Tate added: "Medical repatriation is incredibly expensive — especially as the only way Holly can fly home is on a stretcher.
"Requiring, a specialist medical flight with trained staff to monitor her throughout the journey.
"Unfortunately, this is not covered by insurance."
4
4
It comes after a 22-year-old Brit holidaymaker was injured after falling off a boat in Magaluf.
He is said to have been drinking on the rented boat before falling and cutting himself.
The Brit was taken to Son Espases Hospital in the Majorcan capital Palma.
Elsewhere, another Brit tourist died from severe head injuries after falling from a window in the Netherlands.
Ben Roberts, 24, suffered a fractured skull when he fell
His mother Kerry said: "I can't describe our loss, we are heartbroken.
"As Ben's mum, part of me died the day he did."
What to do if you're injured on holiday
No one sets off on holiday expecting to be injured, but it's vital to be aware of what to do if accidents happen.
If you booked a package holiday, then your tour operator or organiser should have measures in place to help you if you fall ill or are injured.
But if you book your own travel and accommodation, it's especially vital to have travel insurance in place.
Uninsured travellers can end up facing vast medical and repatriation expenses if the worst happens.
The most comprehensive travel insurance plans can help cover medical emergencies and sometimes support in returning home if needed.
Citizens Advice website says: "It's particularly important to take out travel insurance if you are travelling independently because you may find yourself stranded with no way to get home and no-one to help sort out your holiday problem."
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Times
3 hours ago
- Times
A woman has died after being licked by a dog. Here's what you need to know
They share our sofa and sprawl across our laps. But should we let our dogs lick us? Last week it emerged that June Baxter, 83, a retired legal secretary, died of septic shock after her leg injury was licked by a dog and this led to an infection. Tests from the wound found Pasteurella multocida, a bacteria present in about 50 per cent of dogs' mouths, which typically does a dog no harm. No, although very few incidents of serious injury or death caused by Pasteurella multocida from a dog lick have been recorded. They include an 85-year-old woman with a pet dog who had Pasteurella multocida and died with multiple organ failure after developing septic shock. In 2023 the case report authors in the journal BMC Geriatrics said that highlighting her death was 'important, given the growing cohort of elderly pet-owners seeking medical care'.
The Guardian
3 hours ago
- The Guardian
Demand for weight loss drugs is becoming unsustainable, say pharmacists
Demand for weight loss drugs is becoming so 'unsustainable' that demand may soon outstrip supply, pharmacists have warned. The National Pharmacy Association (NPA) said supply problems could encourage people to turn to unregulated online sources, despite the risks involved. The number of people in the UK using drugs such as Wegovy and Mounjaro has soared to well above a million, with most patients paying to get them privately. During April, 1.6m packs of Mounjaro and Wegovy were bought in Britain, with the number thought to correlate closely with the number of people using them. 'Spiralling demand for weight loss medication risks going far beyond what is clinically deliverable', the NPA said. The drugs might need to be reserved for those in greatest need because they are so overweight instead of being given to the 'worried well', it added. New polling has found that 21% of Britons have tried to get hold of the medications over the past year, a figure that rises to 35% among 18- to 34-year-olds. The same survey found that 41% of all age groups would use them if they were free on the NHS. This figure rose to 64% among those aged 25-34. Savanta interviewed a representative sample of 2,002 adults aged 18 or over online from 20-23 June for the NPA, which represents 6,000 independent pharmacies. 'Weight loss jabs are one of the biggest drug innovations this century but growing demand for weight loss treatment highlights the need to make sure this is appropriate for those who want it,' said Olivier Picard, the NPA's chair. 'It's clear from this polling that more people are interested in getting weight loss jabs than can benefit from weight loss medication.' Supply of the medicines has been hit by shortages in some parts of the UK, including for higher doses of Mounjaro, the NPA said. Supply has been restricted to some pharmacies, which has stopped some new patients from going on to the drugs. The Medicines and Healthcare products Regulatory Agency, the UK's drugs watchdog, has warned patients to obtain the drugs only with a doctor's prescription, and not from beauty parlours or websites. A Department of Health spokesperson said more people would be able to obtain 'revolutionary' weight loss jabs over the next few years. 'Weight loss drugs are a powerful tool in tackling the obesity crisis head-on as part of our 10-year health plan', they added. 'This government is committed to ensuring that more people have access to these revolutionary drugs when needed, and crucially that they are able to do so in a safe and controlled way. We will ensure that those most in need will receive treatment first.' About 220,000 people in England are due to be offered tirzepatide, a diabetes drug that promotes weight loss, over the next three years. Pharmacies already provide about 85% of all weight loss drugs and need to be closely involved in the expansion of access, Picard added. 'The government should use the massive untapped expertise and skills of pharmacists to help speed up the NHS's weight loss medication programme to millions of the most in need patients,' he said.
Reuters
4 hours ago
- Reuters
Roche to investigate whether new drug can delay or prevent Alzheimer's disease
July 27 (Reuters) - Swiss drugmaker Roche Holding (ROG.S), opens new tab plans to investigate whether an experimental medicine can delay or prevent Alzheimer's disease symptoms, it said on Sunday, as a part of the company's growing development programme for the disease. The clinical trial of the drug, Trontinemab, will target people who are at risk of cognitive decline and will aim to delay or prevent the symptoms of Alzheimer's, Roche said in a statement. Trontinemab is designed so that the drug is transported across the blood brain barrier—protective blood vessels that prevent chemicals in the bloodstream from entering the brain — in hopes of delivering more of the treatment to the brain. Rivals like Eli Lilly (LLY.N), opens new tab have been making progress in the complicated field of Alzheimer's recently, with Lilly's drug Kisunla getting a recommendation for approval for certain patients from the European Medicines Agency last week. Kisunla is already approved in the U.S. Treatments for Alzheimer's approved so far, including Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Leqembi and Lilly's Kisunla, are designed to clear sticky clumps of a protein called amyloid beta in the brain. They carry hefty price tags as well as the risk of serious brain swelling and bleeding.
